NYSE · Healthcare · Financials
Merck & Company, Inc. (MRK) financial statements and cash flow.
Revenue, profitability, balance-sheet strength, and cash generation for MRK. Market data source · as of 2026-06-30.
Section freshness
Price Aug 19, 3:44 PM EDT · Statements Jun 29, 8:00 PM EDT
Financial read
MRK latest financial snapshot.
Start with the latest reported values below. Deeper quarterly and annual statement tables follow when supplied.
Revenue
$16.61B
+5.1% YoY
Net income
-$1.33B
+68.5% QoQ
Free cash flow
$4.48B
+53.0% QoQ
Net margin
-8.04%
Balance sheet coverage
MRK balance sheet summary
Assets, liabilities, liquidity, debt, and equity sit beside income and cash-flow tables so the statement history reads as one model-ready dataset.
20 quarterly · 4 annual rows · Market data source · as of 2026-06-30
Latest period
Q2 FY2026
20 quarterly · 4 annual rows
Assets / liabilities
$129.80B
Liabilities —
Cash / debt
$6.85B
Net cash -$47.06B
Equity / working capital
$41.93B
Working capital $8.95B
Financial statements
MRK statement coverage.
Income statement, balance sheet, and cash-flow figures for MRK, with quarterly and annual history in the tables below.
Data last updated
Jun 29, 2026
Income periods
24
Balance-sheet periods
24
Cash-flow periods
24
Quarterly and annual MRK statements, sourced from Market data source · as of 2026-06-30.
Financial statement period
MRK statement history
Market data source · as of 2026-06-30 · Data last updated: Jun 29, 2026
Income statement
Quarterly and annual rows for revenue, operating leverage, earnings quality, and margin direction.
| Period | Revenue | Gross profit | Operating income | Interest income | Continuing ops | Net income | Comprehensive income | Net margin | Revenue QoQ | Net income QoQ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $16.61B | -$1.33B | -8.04% | +2.0% | +68.5% | |||||
| Q1 FY2026 | $16.29B | -$4.24B | -26.03% | -0.7% | -243.1% | |||||
| Q4 FY2025 | $16.40B | $2.96B | 18.07% | -5.1% | -48.8% | |||||
| Q3 FY2025 | $17.28B | $5.79B | 33.49% | +9.3% | +30.7% | |||||
| Q2 FY2025 | $15.81B | $4.43B | 28.01% | +1.8% | -12.8% | |||||
| Q1 FY2025 | $15.53B | $5.08B | 32.71% | -0.6% | +35.7% | |||||
| Q4 FY2024 | $15.62B | $3.74B | 23.96% | -6.2% | +18.6% | |||||
| Q3 FY2024 | $16.66B | $3.16B | 18.95% | +3.4% | -42.1% |
Balance sheet
Balance-sheet history for assets, liabilities, liquidity, debt, equity, and shares outstanding.
| Period | Cash | Current assets | Current liabilities | Total assets | Total liabilities | Total debt | Capital leases | Total equity | Shares | Debt QoQ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $6.85B | $36.68B | $27.73B | $129.80B | $53.91B | $41.93B | +9.8% | |||
| Q1 FY2026 | $5.33B | $35.02B | $26.95B | $128.69B | $49.12B | $45.88B | -0.4% | |||
| Q4 FY2025 | $14.56B | $43.52B | $28.33B | $136.87B | $49.34B | $52.61B | +19.3% | |||
| Q3 FY2025 | $18.17B | $47.56B | $28.63B | $129.55B | $41.37B | $51.85B | +16.9% | |||
| Q2 FY2025 | $8.01B | $37.06B | $26.04B | $117.52B | $35.40B | $48.99B | +1.6% | |||
| Q1 FY2025 | $8.63B | $35.50B | $25.17B | $115.12B | $34.84B | $48.34B | -6.1% | |||
| Q4 FY2024 | $13.24B | $38.78B | $28.42B | $117.11B | $37.11B | $46.31B | -2.7% | |||
| Q3 FY2024 | $14.59B | $40.36B | $29.59B | $117.53B | $38.13B | $44.50B | +0.9% |
Cash flow
Operating cash generation, capital expenditure, free cash flow, buybacks, dividends, and cash movement.
| Period | Operating cash flow | CapEx | Free cash flow | Net income | Stock comp | Debt issuance | Dividends paid | Buybacks | Change in cash | FCF QoQ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $5.37B | $893.00M | $4.48B | -$1.33B | $2.14B | $757.00M | +53.0% | |||
| Q1 FY2026 | $3.92B | $991.00M | $2.93B | -$4.24B | $2.10B | $874.00M | +60.5% | |||
| Q4 FY2025 | $2.86B | $1.03B | $1.82B | $2.96B | $2.02B | $1.25B | -73.3% | |||
| Q3 FY2025 | $7.82B | $987.00M | $6.83B | $5.79B | $2.03B | $1.32B | +170.3% | |||
| Q2 FY2025 | $3.29B | $764.00M | $2.53B | $4.43B | $2.08B | $1.34B | +115.8% | |||
| Q1 FY2025 | $2.50B | $1.33B | $1.17B | $5.08B | $2.05B | $1.16B | -53.4% | |||
| Q4 FY2024 | $3.45B | $937.00M | $2.51B | $3.74B | $1.95B | $489.00M | -70.5% | |||
| Q3 FY2024 | $9.29B | $783.00M | $8.51B | $3.16B | $1.95B | $444.00M | +75.6% |
Valuation and returns
- Enterprise value
- $423.15B
- TECHi computed
- Return on equity
- 7.57%
- Market data source
- Return on assets
- 2.44%
- Market data source
- Debt / equity
- 1.29
- Current ratio 1.32
Ratio values use provider-attributed fields when available and otherwise fall back to TECHi statement math from the visible rows on this page.
Annual revenue and income multiples
Annual sales and income multiple reads use the latest annual statement when available, then fall back to trailing-twelve-month statement math from the visible quarterly rows.
- Annual revenue base
- $65.01B
- Annual statement 2025-12-31
- Annual income base
- $18.25B
- Annual statement 2025-12-31
- Market cap / annual revenue
- 5.79
- Live market value divided by annual revenue
- Market cap / annual income
- 20.60
- Live market value divided by annual net income
Annual sales and income multiple
Market capitalization bridge
TTM valuation multiples
- TTM revenue
- $66.57B
- Trailing twelve months
- Market cap / TTM revenue
- 5.65
- Live market value divided by trailing twelve months revenue
- EV / TTM revenue
- 6.36
- Enterprise value divided by trailing twelve months revenue
Live market value is matched against trailing-twelve-month statement bases first so the multiple moves with the tape instead of anchoring to stale fiscal-year rows.
Profit multiples
Revenue, net income, and free cash flow
Quarterly statement rows, shown on one common dollar scale so margin compression and cash conversion stand out quickly.
Efficiency
Growth vs cost pressure
Cash conversion
Quarterly margin heatmap
Latest quarter expense mix
Profit bridge
Other income statement lines
Balance sheet · Q2 FY2026
- Cash & equivalents
- $6.85B
- Total debt
- $53.91B
- Net cash
- -$47.06B
- Net debt position
- Total equity
- $41.93B
Balance sheet detail
- Current assets
- $36.68B
- Current liabilities
- $27.73B
- Inventory
- $6.21B
- Receivables
- $12.56B
- Property, plant & equipment
- $25.74B
- Current debt
- $2.83B
- Long-term debt
- $51.08B
Debt and liquidity
Cash + short-term investments + receivables / current liabilities
Cash generation
- Operating cash flow
- $5.37B
- Capital expenditure
- $893.00M
- Free cash flow
- $4.48B
- Capital returned
- $2.90B
- Buybacks + dividends paid
Cash-flow detail
- Investing cash flow
- -$5.60B
- Financing cash flow
- $1.76B
- Stock issuance
- $43.00M
- Common stock issued
- Buybacks
- $757.00M
- Net buybacks
- $714.00M
- Repurchases less stock issuance
- Dividends paid
- $2.14B
Cash flow read
MRK runs cash-flow positive.
MRK is generating $4.48B of free cash, which funds buybacks ($757.00M) and dividends ($2.14B) without leaning on the balance sheet. Watch the gap between FCF and net income — a widening gap is usually working-capital noise; a persistent gap is a signal.
Frequently asked
Common questions.
What financial data is available for MRK?
The MRK Financials page renders only the current income-statement, balance-sheet, cash-flow, or fund rows supplied for Merck & Company, Inc.. Missing modules and empty line items are omitted.
How current are MRK's financial statements?
Each visible statement row keeps its reported period and provider attribution. The route redirects to the main quote when no usable financial or fund data remains.
What is Merck & Company, Inc.'s reported net margin?
Merck & Company, Inc.'s fresh reported margin field is 4.77%. The Financials page shows the supporting period data currently available for MRK.